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Abstract: Five new indole alkaloids rauvotetraphyllines A–E (1–5), together with eight known analogues, were isolated from the 
aerial parts of Rauvolfia tetraphylla. The structures were established by means of spectroscopic methods. 
Keywords: Rauvolfia tetraphylla, indole alkaloid, rauvotetraphylline
Introduction 
Rauvolfia genus, family Apocynaceae, continues to be  
fascinating as it produces novel heterocyclic alkaloids with 
monoterpene indole skeletons, which have attracted great  
interests from biological and therapeutic aspects, due to their 
anticancer,1 antimalarial,2 antihypertensive,3 and sedative4 
properties. The isolation and structure elucidation of three 
indole alkaloids rauvoyunines A, B, and C from the aerial 
parts of Rauvolfia yunnanensis have been reported earlier.5 As 
one part of our ongoing research program exploring bioactive 
indole alkaloids from Chinese species of Rauvolfia,  
phytochemical analysis has been carried out on the aerial parts 
of R. tetraphylla collected from Yunnan Province, with  
particular attention to the monoterpene indole constituents, and 
has resulted in the isolation of five new alkaloids,  
rauvotetraphyllines A–E (1–5), as well as eight known  
analogues, alstonine (6),6 nortetraphyllicine,7 peraksine,8 
sarpagine,9 3-hydroxysarpagine,10 dihydroperaksine,11 10-
hydroxydihydroperaksine,11 and raucaffricine.12 The present 
paper reports the isolation, structure elucidation, and cytotoxic 
evaluation of the new compounds. 
 
Results and Discussion 
Compound 1, obtained as amorphous powder, had a 
molecular formula of C20H26N2O3 based on HRESIMS (pos.) 
at m/z 343.2024 (calcd for C20H27N2O3, 343.2021). In the UV 
spectrum, two noticeable maxima absorption bands at 211 and 
275 nm as well as two shoulders at 222 and 310 nm were 
detected, suggesting the existence of an O-substituted indole 
chromophore.13 The IR spectrum showed band at 3407 cm–1, 
due to OH/NH functionalities. The 1H NMR spectrum (Table 1) 
showed signals for an aromatic AMX spin system at δH 6.62 
(dd, J = 8.5, 2.0 Hz), 6.82 (d, J = 2.0 Hz), and 7.11 (d, J = 8.5 
Hz), typical of an indole moiety substituted by a hydroxy 
group at C-10 or C-11 position, signals characteristic of an 
ethylidene group at δH 1.16 (d, J = 6.3 Hz) and 5.51 (q, J = 6.3 
Hz), protons for N-methyl group at δH 2.47 (s), and protons of 
two oxygenated methylene groups, one at δH 3.57 (dd, J = 11.1, 
4.0 Hz) and 3.32 (dd, J = 11.1, 10.6 Hz), and another at δH 
4.04 and 4.08 (each d, J = 13.4 Hz). In addition to resonances 
due to indole chromophore including an oxygen-bearing 
carbon at δC 151.2 (s), the 13C NMR (DEPT) spectrum (Table 
2) exhibited signals ascribed to one double bond at δC 123.6 (d) 
and 140.6 (s), two oxygenated carbons at δC 62.9 (t) and δC 
63.2 (t), two methyl signals at δC 12.7 (q) and 41.7 (q), and the 
other six aliphatic carbons. These spectroscopic features 
resembled rauvoyunine A,5 a macroline-type alkaloid recently 
isolated from R. yunnanensis, except for the absence of an  
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constants in ring D. The position of the N-methyl group was 
confirmed by HMBC correlations from N(4)-Me to C-3 and  
C-5, while the location of the hydroxy group was confirmed 
by HMBC correlation from an m-coupling doublet of H-9 at δH 
6.82 (d, J = 2.0 Hz) to C-7 and ROESY correlation between 
H-9 and H-6β (Figure 1). Since the J5,6, J3,14, and J14,15 values 
corresponding to vicinal interaction (3JH,H) were essentially 
unchanged compared to those of rauvoyunine A, it is safe to 
deduce that the C/D ring junction stereochemistry remained 
intact, whereas revealing as the major difference from 
rauvoyunine A, the J values between H-15 and H-16 (1: J = 
11.8 Hz; rauvoyunine A: J = 5.6 Hz), H-5 and H-16 (1: J = 5.0 
Hz; rauvoyunine A: J ≈ 0 Hz), and H-16 and H2-17 (1: J = 
10.6 and 4.0 Hz; rauvoyunine A: J = 5.5 and 3.7 Hz) strongly 
suggested that this new compound had a macroline-type 
skeleton with the unique feature of a 16-epi (16αH) form. 
Consistent with this deduction, the ROESY spectrum of 1 
showed cross-peaks of H-15↔H2-17 and H2-17↔H-6β. The 
C-19–C-20 double bond had the E-configuration since the 
ROESY correlations of Me-18↔H-15 and H-19↔H2-21 were 
observed. Thus, the structure of the new alkaloid was 
established as shown, named rauvotetraphylline A. 
Compound 2, obtained as amorphous powder, possessed a 
molecular formula of C31H37N3O6, as evidenced by HRESIMS 
(pos.) at m/z 548.2768, in combination with NMR spectra 
(Tables 1 and 2), requiring 15 degrees of unsaturation. The 
NMR spectra exhibited a β-glucopyranosyl unit (δC 102.8, 
75.3, 78.1, 71.5, 78.0, 62.8), and a set of resonances [δC 121.0 
(d), 150.1 (s), 123.6 (d), 158.4 (s), 21.0 (q), 23.6 (q); δH 7.02 
(s), 6.96 (s), 2.30 (s), 2.39 (s)] which can be easily determined 
as a 4,6-dimethyl-2-pyridyl moiety.14 The remainder were 
closely related to those of vellosimine15—a sarpagine-type 
alkaloid, except for the absence of an aldehyde group, as well 
as an unusual low-field methine signal at δC 91.8 instead of a 
methylene signal for C-21. The significant downfield shift for 
C-21 suggested that the sugar unit was adjacent to C-21, as 
supported by HMBC correlation from the anomeric proton of 
β-glucose at δH 4.70 (d, J = 7.8 Hz) to C-21. Considering that 
it lacks an aldehyde group at C-16, which is usual for the 
sarpagine series such as 12-methoxy-vellosimine16 or 
dihydroperaksine-17-al11 from species of Rauvolfia, the 4,6-
dimethyl-2-pyridyl moiety was assumed to be an artifact 
(produced by aldehyde-ammonia condensation reaction) 
linked to C-16 since acetone and NH3·H2O were used as eluent 
during the isolation process. The above deduction was 
confirmed by HMBC correlations from H-5 and H-15 to C-17, 
and H-16 to C-17 and C-22. ROESY correlations of H-5↔H-
6α (strong), H-5↔H6β (slight), H-3↔H-5 (slight), H-6β↔H-
16, and H-16↔H-14β suggested that the new alkaloid had the 
same ring junction stereochemistry as that of vellosimine, 
Table 1. 1H NMR data for compounds 1−5 (δ in ppm, J in Hz) 
No. 1a 2a 3a 4b 5c
3 3.92 (br. s) 4.80 (br. d, 10.2) 4.76 (br. d, 10.2) 4.18 (d, 9.3)  
5 3.47 (dd, 6.7, 5.0) 3.67 (dd, 8.0, 5.1) 2.98 (dd, 7.1, 5.1) 3.66 (dd, 5.1, 4.9) 8.44 (d, 6.3) 
6 2.92 (dd, 17.0, 6.7, Hα) 
2.69 (d, 17.0, Hβ) 
3.07 (dd, 15.3, 5.1, Hα) 
2.59 (d, 15.3, Hβ) 
3.02 (dd, 15.1, 5.1, Hα) 
2.63 (d, 15.1, Hβ) 
1.63 (d, 12.0, Hα) 
2.81 (dd, 12.0, 4.9, Hβ) 
8.51 (d, 6.3) 
9 6.82 (d, 2.0) 7.35 (dd, 7.8, 0.6) 7.39 (dd, 7.8, 0.8) 7.47 (dd, 7.3, 0.7) 8.37 (d, 8.0) 
10  6.95 (ddd, 7.8, 7.2, 0.6) 6.97 (ddd, 7.8, 7.1, 0.8) 7.22 (ddd, 7.6, 7.3, 0.7) 7.31 (dd, 8.0, 7.1) 
11 6.62 (dd, 8.5, 2.0) 7.04 (ddd, 8.0, 7.2, 0.9) 7.05 (ddd, 8.0, 7.1, 1.0) 7.39 (ddd, 7.7, 7.6, 1.1) 7.63 (dd, 8.4, 7.1) 
12 7.11 (d, 8.5) 7.29 (dd, 8.0, 0.9) 7.28 (dd, 8.0, 1.0) 7.61 (dd, 7.7, 1.1) 7.84 (d, 8.4) 
14 2.19 (ddd, 12.9,12.0, 2.7, Hα) 
1.53 (br. d, 12.9, Hβ) 
2.17 (m, Hα) 
1.89 (m, Hβ) 
2.13 (m, Hα) 
1.71 (m, Hβ) 
1.97 (dd, 15.3, 9.3, Hα) 
1.58 (dd, 15.3, 3.8, Hβ) 
4.56 (dd, 17.3, 6.8) 
3.37 (m) 
15 2.42 (ddd, 12.0, 11.8, 3.2) 2.84 (br. s) 2.76 (br. s) 2.40 (m, overlap) 3.12 (m) 
16 2.32 (dddd, 11.8, 10.6, 5.0, 4.0) 3.11 (br. d, 8.0) 2.46 (dd, 9.1, 7.1) 2.40 (m, overlap)  
17 3.57 (dd, 11.1, 4.0) 
3.32 (dd, 11.1, 10.6) 
 6.73 (dd, 15.8, 9.1) 4.92 (s) 7.28 (s) 
18 1.16 (d, 6.3) 1.15 (d, 6.8) 1.70 (d, 6.9) 1.23 (d, 6.7) 1.33 (d, 6.0) 
19 5.51 (q, 6.3) 5.88 (q, 6.8) 5.99 (q, 6.9) 2.77 (m) 3.64 (m) 
20    2.06 (m) 2.38 (m) 
21 4.04 (d, 13.4) 
4.08 (d, 13.4) 
5.23 (s) 5.07 (s) 6.84 (dd, 15.9, 7.8) 4.61 (dd, 14.0, 4.7, Hα) 
4.96 (dd, 14.0, 5.7, Hβ) 
22  7.02 (s) 6.06 (d, 15.8) 6.18 (d, 15.9)  
24  6.96 (s) 2.22 (s) 2.28 (s)  
26  2.30 (s)    
27  2.39 (s)    
1′  4.70 (d, 7.8) 4.65 (d, 7.8)   
2′  3.32 (m) 3.30 (m)   
3′  3.39 (m) 3.38 (m)   
4′  3.31 (m, overlap) 3.29 (m, overlap)   
5′  3.31 (m, overlap) 3.29 (m, overlap)   
6′  3.63 (dd, 11.9, 5.0) 
3.80 (br. d, 11.9 ) 
3.61 (dd, 11.8, 5.1) 
3.78 (br. d, 11.8) 
  
OAc    2.16 (s)  
NMe 2.47 (s)     
aMeasured in CD3OD (3.30 ppm); bMeasured in CDCl3 (7.26 ppm); cMeasured in DMSO-d6 (2.50 ppm). 
 
Figure 1.  Key HMBC and ROESY correlations of 1 
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while the proton at C-22 showing cross-peaks with H-5, H-19, 
and H-21 supported exo position of the pyridyl moiety and  
β-orientation of H-21. The Me-18 at δH 1.15 (noticeable 
upfield shift being due to shielding by the pyridyl ring current) 
showed ROESY correlation with H-15 while H-19 exhibited 
correlation with H-21, revealing an E-geometry of the 
ethylidene. Therefore, the structure of 2 was unambiguously 
elucidated as shown, named rauvotetraphylline B.  
Compound 3 was obtained as amorphous powder. High 
resolution mass spectrometry revealed the [M + H]+ peak at 
m/z 511.2431, suggesting the molecular formula C28H34N2O7. 
The NMR signals (Tables 1 and 2) were very similar to those 
of rauvotetraphylline B (2), which revealed that 3 was also a 
sarpagine alkaloid. However, there was a prominent difference 
as follows: the signals assigned to 4,6-dimethyl-2-pyridyl 
moiety in 2 were absent, and there was a set of newly risen 
resonances: δC 151.7 (d), 131.6 (d), 201.1 (s), 27.0 (q); δH 6.73 
(dd, J = 15.8, 9.1 Hz), 6.06 (d, J = 15.8 Hz), and 2.22 (s), 
which was easily assigned as an E-3-oxo-1-butenyl unit. In the 
HMBC spectrum, significant correlations from olefinic proton 
at δH 6.73 to carbons at δC 54.9 (d, C-5), 32.5 (d, C-15), and 
46.8 (d, C-16) were observed, which indicated that the butenyl 
group was also attached to C-16. Other structural parts of 3 
were identical to those of 2, as indicated by the HMBC, HSQC, 
and ROESY spectra. Consequently, the structure of 3 was 
determined as shown, named rauvotetraphylline C. 
Compound 4 was isolated as amorphous powder. Its 
molecular formula was determined as C24H26N2O3 by the 
positive HRESIMS ([M + H]+ at m/z 391.2019). The NMR 
data (Tables 1 and 2) were analogous to those of perakine17—a 
ajmaline-type alkaloid. The principal difference between them 
was the aldehyde group in perakine changing into an E-3-oxo-
1-butenyl unit [δC 146.0 (d), 131.7 (d), 198.0 (s), 27.4 (q); δH 
6.84 (dd, J = 15.9, 7.8 Hz), 6.18 (d, J = 15.9 Hz), 2.28 (s)] on 
the basis of HMBC correlations from H-21 at δH 6.84 to C-15, 
C-19, and C-20. The ROESY correlations of H-3↔H-19↔H-
14α, H-14β↔H-17, and Me-18↔H-20 indicated that 4 
possessed the same stereochemical characteristics as that of 
perakine. Hence, the structure of 4 was assigned as shown, 
named rauvotetraphylline D. 
Compound 5 and alstonine (6) exhibited nearly the same 
UV spectrum, with strong absorption maxima at 252, 308, and 
370 nm. TLC analysis displayed spots with a clear blue 
fluorescence at 365 nm, between which 5 exhibited higher 
polarity. The molecular formula of 5 was determined as 
C20H18N2O3 by HRESIMS, 14 mass units lower than that of 6. 
The 1D NMR data of 5 (Tables 1 and 2) have similar chemical 
shifts and the same multiplicity as given for 6, except for a 
carboxyl group (δC 170.3) in 5 instead of the methoxycarbonyl 
group in 6, as supported by the lack of the methyl ester signals 
in the 1H and 13C NMR spectra and the presence of a hydroxy 
group as IR absorption band at 3423 cm–1 revealed. Other 
structural parts of 5 were identical to those of 6, as indicated 
by the HMBC, HSQC, and ROESY spectra. Thus, the 
structure of the alstonine derivative was established as shown, 
named rauvotetraphylline E. 
All of the new alkaloids were evaluated for their cytotoxicity
in vitro against five human cancer cell lines (HL-60, SMMC-
7721, A-549, MCF-7, and SW-480) using the MTT method as 
reported previously.18 However, all tested compounds were 
inactive, and they showed IC50 values > 40 μM. Considering 
Table 2. 13C NMR data for compounds 1−5 (δ in ppm) 
No. 1a 2a 3a 4b 5c 
2 134.1 (s) 139.3 (s) 139.3 (s) 183.0 (s) 135.1 (s)
3 56.0 (d) 44.9 (d) 44.7 (d) 57.2 (d) 142.2 (s) 
5 55.4 (d) 54.2 (d) 54.9 (d) 50.9 (d) 131.1 (d) 
6 16.6 (t) 27.0 (t) 26.3 (t) 37.5 (t) 115.1 (d) 
7 106.6 (s) 104.6 (s) 104.4 (s) 64.9 (s) 130.1 (s) 
8 128.5 (s) 128.9 (s) 128.8 (s) 136.2 (s) 119.8 (s) 
9 103.1 (d) 118.5 (d) 118.6 (d) 123.8 (d) 122.9 (d) 
10 151.2 (s) 119.8 (d) 119.9 (d) 125.5 (d) 120.4 (d) 
11 111.5 (d) 122.0 (d) 122.1 (d) 128.7 (d) 130.3 (d) 
12 112.3 (d) 112.0 (d) 112.0 (d) 121.0 (d) 114.3 (d) 
13 132.6 (s) 138.2 (s) 138.2 (s) 156.4 (s) 145.7 (s)
14 35.9 (t) 33.8 (t) 32.7 (t) 22.0 (t) 29.5 (t) 
15 31.3 (d) 34.7 (d) 32.5 (d) 30.0 (d) 27.5 (d) 
16 45.7 (d) 50.3 (d) 46.8 (d) 48.6 (d) 114.7 (s) 
17 62.9 (t) 162.8 (s) 151.7 (d) 78.0 (d) 149.8 (d) 
18 12.7 (q) 12.9 (q) 13.4 (q) 17.3 (q) 18.4 (q) 
19 123.6 (d) 126.0 (d) 126.1 (d) 55.0 (d) 69.3 (d) 
20 140.6 (s) 135.6 (s) 136.0 (s) 46.7 (d) 35.7 (d) 
21 63.2 (t) 91.8 (d) 91.7 (d) 146.0 (d) 54.1 (t) 
22  121.0 (d) 131.6 (d) 131.7 (d) 170.3 (s) 
23  150.1 (s) 201.1 (s) 198.0 (s)  
24  123.6 (d) 27.0 (q) 27.4 (q)  
25  158.4 (s)    
26  21.0 (q)    
27  23.6 (q)    
1′  102.8 (d) 102.7 (d)   
2′  75.3 (d) 75.4 (d)   
3′  78.1 (d) 78.1 (d)   
4′  71.5 (d) 71.5 (d)   
5′  78.0 (d) 78.0 (d)   
6′  62.8 (t) 62.8 (t)   
CH3COO   21.1 (q)  
CH3COO    170.0 (s)  
NCH3 41.7 (q)     
aMeasured in CD3OD (49.0 ppm); bMeasured in CDCl3 (77.0 ppm); cMeasured in DMSO-d6 (39.5 ppm). 
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the structural characteristics of the new compounds, we 




General Experimental Procedures. Optical rotations were 
measured on a Jasco P-1020 automatic digital polarimeter. IR 
spectra were obtained using a Bruker Tensor 27 FT-IR  
spectrometer with KBr pellets. UV data were obtained from 
online HPLC analysis. NMR spectra were acquired with a 
Bruker DRX-500 instrument at room temperature. ESIMS 
(including HRESIMS) were measured on API QSTAR  
Pulsar i mass spectrometers. Silica gel (200−300 mesh, Qing-
dao Marine Chemical Inc., China), Sephadex LH-20  
(Amersham Biosciences, Sweden) and MCI gel CHP 20P 
(75−150 μm, Mitsubishi Chemical Corp., Tokyo, Japan) were 
used for column chromatography. Medium pressure liquid 
chromatography (MPLC) was performed on a Büchi Sepacore 
System equipping pump manager C-615, pump modules  
C-605, and fraction collector C-660 (Büchi Labortechnik AG, 
Switzerland), and columns packed with Chromatorex C-18 
(40−75 μm, Fuji Silysia Chemical Ltd., Japan). Fractions were 
monitored by TLC (Qingdao Marine Chemical Inc., China) in 
combination with reversed-phase HPLC (Agilent 1200,  
Extend-C18 column, 5 μm, 4.6 × 150 mm). 
 
Plant Material. The aerial parts of R. tetraphylla were  
collected in Xiaomenglun of Yunnan Province, China, in June 
2010 and were identified by Prof. Yu Chen of Kunming  
Institute of Botany, Chinese Academy of Sciences. The 
voucher specimen was deposited at BioBioPha Co., Ltd. 
 
Extraction and Isolation. The air-dried and powdered  
aerial parts of R. tetraphylla (7.5 kg) were extracted three 
times with 95% ethanol (3 × 50 L, each 3 days) at room  
temperature and filtered. The filtrate was evaporated under 
reduced pressure to get a residue (ca. 400 g), which was  
fractionized by silica gel column chromatography, eluted with 
a gradient solvent system of petroleum ether-acetone and then 
MeOH to yield six fractions A–F. Fraction F, eluted by MeOH, 
was separated on silica gel CC (CHCl3-MeOH, 50:1 → 0:1, 
v/v) to give five subfractions (F1–F5), Compounds 4 (6 mg) 
and 7 (7 mg) were obtained from the subfraction F1 by silica 
gel (CHCl3-MeOH-NH3·H2O, 50:1:0.1) and Sephadex LH-20 
(MeOH) columns. Fraction F2 was separated by silica gel 
(CHCl3-MeOH-NH3·H2O, 40:1:0.1 → 5:1:0.1), MCI (50% → 
100% MeOH in water), and Sephadex LH-20 (MeOH)  
columns to afford 8 (230 mg), 9 (94 mg), and 10 (84 mg). In 
the same way, 1 (119 mg) and 11 (29 mg) were isolated from 
fraction F3. Also, 12 (83 mg) and 6 (3 mg) were obtained from 
fractions F4. After repeated silica gel (CHCl3-MeOH-
NH3·H2O, 10:1:0.1 → 1:1:0.05), Sephadex LH-20 (CHCl3-
MeOH, 1:1), and MPLC (30% → 50% MeOH in H2O),  
fraction F5 afforded 13 (135 mg), 3 (26 mg), 2 (21 mg), and 5 
(272 mg). The retention times (tR) of new compounds 1–5 
from analysis-type HPLC (20% → 80% MeOH in H2O over 
8.0 min followed by 100% MeOH to 10 min, 1.0 ml/min, 
20 °C) were 7.8, 8.8, 7.9, 8.4, and 6.7 min, respectively. 
 
Rauvotetraphylline A (1): yellowish, amorphous powder; 
[α]16D   +16.2 (c 0.20, MeOH); UV (MeOH) max: 211, 222 (sh), 
275, 310 (sh) nm; IR (KBr) max 3407, 2923, 2892, 1630, 1596, 
1454, 1382, 1364, 1236, 1190, 1144, 1114, 1059, 997, 798, 
743 cm–1; 1H and 13C NMR data see Tables 1 and 2; ESIMS 
(pos.): m/z 343 [M + H]+; HRESIMS (pos.): m/z 343.2024 
(calcd for C20H27N2O3, 343.2021). 
 
Rauvotetraphylline B (2): yellowish, amorphous powder; 
[α]16D   +52.7 (c 0.21, MeOH); UV (MeOH) max: 225, 265 (sh), 
272, 282 (sh), 290 (sh) nm; IR (KBr) max 3406, 2921, 2856, 
1608, 1568, 1452, 1411, 1384, 1335, 1238, 1170, 1075, 1026, 
743 cm–1; 1H and 13C NMR data see Tables 1 and 2; ESIMS 
(pos.): m/z 548 [M + H]+; HRESIMS (pos.): m/z 548.2768 
(calcd for C31H38N3O6, 548.2760). 
 
Rauvotetraphylline C (3): yellowish, amorphous powder; 
[α]16D   +31.4 (c 0.19, MeOH); UV (MeOH) max: 225, 270, 284 
(sh), 293 (sh) nm; IR (KBr) max 3405, 2918, 1669, 1622, 1572, 
1452, 1419, 1384, 1362, 1335, 1259, 1238, 1170, 1075, 1025, 
746 cm–1; 1H and 13C NMR data see Tables 1 and 2; ESIMS 
(pos.): m/z 511 [M + H]+; HRESIMS (pos.): m/z 511.2431 
(calcd for C28H35N2O7, 511.2444). 
 
Rauvotetraphylline D (4): yellowish, amorphous powder; 
[α]14D   +26.5 (c 0.20, CHCl3); UV (MeOH) max: 221, 226 (sh), 
253 (sh) nm; IR (KBr) max 3431, 2964, 2931, 1741, 1695, 
1673, 1620, 1592, 1468, 1453, 1363, 1231, 1177, 1138, 1034, 
980, 952, 774, 753 cm–1; 1H and 13C NMR data see Tables 1 
and 2; ESIMS (pos.): m/z 391 [M + H]+; HRESIMS (pos.): m/z 
391.2019 (calcd for C24H27N2O3, 391.2021). 
 
Rauvotetraphylline E (5): yellowish, amorphous powder; 
[α]15D   +136.8 (c 0.20, MeOH); UV (MeOH) max: 218 (sh), 234 
(sh), 252, 260 (sh), 308, 370 nm; IR (KBr) max 3423, 3066, 
2976, 2907, 1639, 1550, 1529, 1504, 1448, 1384, 1364, 1332, 
1250, 1180, 1129, 790, 754 cm–1; 1H and 13C NMR data see 
Tables 1 and 2; ESIMS (pos.): m/z 335 [M + H]+; HRESIMS 
(pos.): m/z 335.1388 (calcd for C20H19N2O3, 335.1395). 
 
Cytotoxicity Assay. The cytotoxicity assay was performed 
according to the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] method,19 by use of the following
five human cancer cell lines: human myeloid leukemia HL-60, 
hepatocellular carcinoma SMMC-7721, lung cancer A-549, 
breast cancer MCF-7, and colon cancer SW-480. The IC50 
values were calculated by Reed and Muench’s method.20 
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